Recap: Aligos Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Aligos Therapeutics (NASDAQ:ALGS) reported Q4 earnings, beating estimates with an EPS of $-0.22 against an expected $-0.27. However, revenue decreased by $1.53 million from the previous year. The company had previously seen a 1.0% stock price increase following last quarter's earnings beat.
March 12, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Aligos Therapeutics reported a Q4 earnings beat with an EPS of $-0.22, surpassing the expected $-0.27, but saw a decrease in revenue by $1.53 million from the previous year.
While Aligos Therapeutics beat earnings estimates, the decrease in revenue could temper investor enthusiasm, leading to a neutral short-term impact on the stock price. Historical data shows a positive reaction to earnings beats, but revenue declines are generally viewed negatively by the market.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100